QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wolfe-research-upgrades-edwards-lifesciences-to-peer-perform

Wolfe Research analyst Mike Polark upgrades Edwards Lifesciences (NYSE:EW) from Underperform to Peer Perform.

 jefferies-upgrades-edwards-lifesciences-to-buy-raises-price-target-to-98

Jefferies analyst Matthew Taylor upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $...

 truist-securities-maintains-hold-on-edwards-lifesciences-raises-price-target-to-87

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Hold and raises the price target ...

 edwards-lifesciences-reports-encircle-mitral-trial-met-primary-and-secondary-endpoints-evoque-tricuspid-registry-shows-superior-real-world-outcomes-versus-pivotal-trial

ENCIRCLE mitral trial achieves primary and secondary endpoints EVOQUE tricuspid valve registry demonstrates more favorable out...

 edwards-lifesciences-announces-7-yr-data-from-partner-3-trial-reaffirming-early-and-sustained-patient-benefits-of-edwards-tavr

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven yearsEdwards...

 oppenheimer-downgrades-edwards-lifesciences-to-perform

Oppenheimer analyst Suraj Kalia downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Perform.

 evercore-isi-group-upgrades-edwards-lifesciences-to-outperform-raises-price-target-to-88

Evercore ISI Group analyst Vijay Kumar upgrades Edwards Lifesciences (NYSE:EW) from In-Line to Outperform and raises the pri...

 heres-how-much-you-would-have-made-owning-edwards-lifesciences-stock-in-the-last-20-years

Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an...

 stifel-maintains-buy-on-edwards-lifesciences-lowers-price-target-to-85

Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $95 to $85.

 israel-englanders-millennium-goes-all-in-on-crypto-and-healthcare-while-rebalancing-big-tech-bets-bitcoin-etf-and-palantir-stakes-soar-in-q2

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalanc...

 deal-dispatch-performance-food-group-and-claires-lead-a-week-of-big-auctions-retail-woes

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid ret...

 ftc-sounds-alarm-on-edwards-attempt-to-corner-heart-device-market

The FTC complaint alleges that if Edwards acquires JenaValve, it would gain control over the two most advanced TAVR-AR devices.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION